Hydroxyurea Dosing for Pediatric Patients
For children with sickle cell anemia (HbSS or Sβ⁰-thalassemia), start hydroxyurea at 15-20 mg/kg/day orally once daily at 9 months of age, then escalate every 8 weeks by 2.5-5 mg/kg increments to a maximum tolerated dose (MTD) of 20-35 mg/kg/day, targeting mild myelosuppression while maintaining absolute neutrophil count ≥1.0 × 10⁹/L and platelets ≥100 × 10⁹/L. 1, 2, 3
Initial Dosing Strategy
The standard approach begins with 15-20 mg/kg/day as a single daily oral dose 3, 4. This can be initiated as early as 9 months of age for children with HbSS or Sβ⁰-thalassemia, even without clinical symptoms 1, 2. For children with severe hemolytic anemia, chronic organ damage, or clinical complications, consider starting at 6 months of age 2.
Important caveat: For children with HbSC or Sβ⁺-thalassemia who exhibit severe disease manifestations (≥3 pain admissions per 2 years, acute chest syndrome, or avascular necrosis), start at the lower end (15 mg/kg/day) due to increased risk of cytopenia in these genotypes 2.
Dose Escalation Protocol
After 6 months at the initial fixed dose, escalate by 2.5-5 mg/kg increments every 8 weeks 3, 4. The goal is to reach MTD, defined as the highest dose that produces mild myelosuppression without unacceptable toxicity 5, 6. Most children reach MTD at 25-30 mg/kg/day, though the range extends to 35 mg/kg/day 5, 6, 7.
Target Laboratory Parameters at MTD:
- Hemoglobin ≥9 g/dL
- Fetal hemoglobin (HbF) ≥20%
- Absolute neutrophil count (ANC) ≥1.0 × 10⁹/L (mild neutropenia is therapeutic)
- Platelet count ≥100 × 10⁹/L
Monitoring Requirements
Before initiation: Obtain complete blood count with differential, absolute reticulocyte count, comprehensive metabolic panel with lactate dehydrogenase, and percent fetal hemoglobin 2.
During treatment: Monitor CBC and reticulocyte count every 1-3 months depending on treatment duration and dose stability 1. Check HbF at least once yearly to assess medication effect and adherence 2.
Alternative Dosing for Special Populations
Low-Resource Settings
Evidence from sub-Saharan Africa demonstrates that starting at 17.5 mg/kg/day (±2.5 mg/kg) is feasible and effective, with subsequent escalation to MTD 3, 4. This approach achieved 94.2% retention at 3 years and significantly reduced vaso-occlusive episodes (IRR 0.45), infections, malaria, transfusions, and death 3.
Ethnic Neutropenia Considerations
In populations with baseline ethnic neutropenia, a lower starting dose of 10-12 mg/kg/day has proven effective and safe, with comparable clinical outcomes to standard dosing 8. This cautious approach prevents excessive myelosuppression while maintaining efficacy.
Renal Impairment
Reduce the dose by 50% (to 7.5 mg/kg/day) in children with creatinine clearance <60 mL/min or end-stage renal disease 9. On dialysis days, administer hydroxyurea following hemodialysis 9.
Formulation and Administration
Hydroxyurea is available as capsules (500 mg), fast-dissolving tablets, or compounded liquid 1. Capsules must be swallowed whole—never opened, broken, or chewed due to cytotoxic properties 9.
Common pitfall: Prescribing exclusively 500 mg capsules often creates complex regimens requiring 3+ capsules daily and alternating doses by day of week, which significantly impairs adherence 10. Consider using multiple capsule strengths or liquid formulation to simplify dosing.
Dose-Limiting Toxicity
Hold or reduce hydroxyurea if:
- ANC <1.0 × 10⁹/L
- Platelets <100 × 10⁹/L
- Hemoglobin <10 g/dL (at lowest dose needed for response)
- Reticulocytes <80 × 10⁹/L (if hemoglobin <9 g/dL)
Recovery from myelosuppression is typically rapid after dose interruption 9. Dose-limiting toxicity rates remain stable (approximately 20-24 per 100 patient-years) across both fixed-dose and MTD phases 4.
Long-Term Efficacy and Safety
Hydroxyurea at MTD provides sustained hematologic efficacy for up to 8 years without adverse effects on growth or increased DNA mutations 5. Extended treatment (median 93 months) demonstrates continued clinical benefit with decreased vaso-occlusive episodes (IRR 0.60), acute chest syndrome (IRR 0.21), infections (IRR 0.52), and serious adverse events (IRR 0.42) when comparing MTD to fixed-dose phases 4.
Critical point: The FDA label states "safety and effectiveness in pediatric patients have not been established" 9, but this reflects regulatory language rather than clinical reality. Extensive guideline and research evidence strongly supports hydroxyurea use in children with sickle cell disease, with the 2014 NHLBI guidelines explicitly recommending initiation at 9 months of age 1, 2.
Contraindications and Precautions
Absolute contraindication: Previous hypersensitivity to hydroxyurea 9.
Prophylactic folic acid is recommended during hydroxyurea therapy 9. Hydroxyurea causes fetal harm and is contraindicated in pregnancy; verify pregnancy status before initiation in adolescent females 9.